Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |3 May 2011

Omalizumab Therapy for Patients With Severe Asthma Free

  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

What is the problem and what is known about it so far?

Asthma is a common disease in which inflammation and constriction of the airways cause symptoms, such as wheezing, coughing, and shortness of breath. In some patients with severe asthma, symptoms persist despite the regular use of inhaled medicines to relax constricted airways (inhaled long-acting β2-agonists [LABAs] or bronchodilators) and to reduce inflammation (inhaled corticosteroids [ICS]). Such patients often require frequent use of a “rescue inhaler” for immediate relief of symptoms and often have acute flares of asthma requiring treatment with steroids given by mouth or by vein.

Why did the researchers do this particular study?

Omalizumab, a medication that blocks the ability of a blood protein to increase airway inflammation and constriction, might help patients with severe asthma. Whether it is helpful in patients with continued symptoms despite ongoing treatment with LABAs and high-dose ICS is not clear.

Who was studied?

850 participants aged 12 to 75 years who had severe asthma causing nighttime awakenings, frequent daytime rescue inhaler use, and at least 1 acute exacerbation of asthma in the past year requiring steroids by mouth or by vein.

How was the study done?

The participants were randomly assigned to receive either omalizumab or a placebo, given as an injection under the skin every 2 or 4 weeks during the 48 weeks of the study. In addition, all participants received treatment with high-dose ICS and LABAs. The researchers measured how often the participants had asthma flares requiring steroids by mouth or by vein, as well as the participants' symptoms, quality of life, and use of rescue inhalers.

What did the researchers find?

During the 48 weeks of the study, participants who received omalizumab had fewer asthma flares requiring steroid therapy by mouth or vein, as well as less use of daytime rescue inhalers, than did the participants who received placebo. The participants who received omalizumab also reported improved asthma symptoms and quality of life compared with the placebo group.

What were the limitations of the study?

Although the researchers saw no difference between the groups in how often bad side effects occurred, the study was too small to confidently assess whether certain rare serious side effects, such as anaphylaxis, blood problems, or cancer, might be increased with the use of omalizumab.

What are the implications of the study?

Omalizumab can improve symptoms and prevent acute asthma flares in some patients with severe asthma despite treatment with LABAs and high-dose ICS.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Omalizumab Therapy for Patients With Severe Asthma. Ann Intern Med. 2011;154:I–28. doi: https://doi.org/10.7326/0003-4819-154-9-201105030-00001

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2011;154(9):I-28.

DOI: 10.7326/0003-4819-154-9-201105030-00001

0 Citations

See Also

Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy: A Randomized Trial
View MoreView Less

Related Articles

Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy: A Randomized Trial
Annals of Internal Medicine; 154 (9): 573-582
As-needed budesonide–formoterol was noninferior to maintenance budesonide for exacerbations in mild asthma
Annals of Internal Medicine; 169 (6): JC30
As-needed budesonide–formoterol better controlled mild asthma vs terbutaline, but maintenance budesonide was better
Annals of Internal Medicine; 169 (6): JC31
Review: Immunotherapy improves some symptoms and reduces long-term medication use in mild to moderate asthma
Annals of Internal Medicine; 169 (4): JC17
View MoreView Less

Journal Club

As-needed budesonide–formoterol was noninferior to maintenance budesonide for exacerbations in mild asthma
Annals of Internal Medicine; 169 (6): JC30
As-needed budesonide–formoterol better controlled mild asthma vs terbutaline, but maintenance budesonide was better
Annals of Internal Medicine; 169 (6): JC31
Review: Immunotherapy improves some symptoms and reduces long-term medication use in mild to moderate asthma
Annals of Internal Medicine; 169 (4): JC17
Azithromycin reduced exacerbations and improved QoL in symptomatic asthma despite inhaled maintenance therapy
Annals of Internal Medicine; 167 (8): JC42
View MoreView Less

Related Point of Care

Asthma
Annals of Internal Medicine; 160 (5): ITC3-1
Asthma
Annals of Internal Medicine; 146 (11): ITC6-1
Allergic Rhinitis
Annals of Internal Medicine; 146 (7): ITC4-1
View MoreView Less

Related Topics

Asthma
Pulmonary/Critical Care

Asthma, Pulmonary/Critical Care.

PubMed Articles

Changes in CD4+CD25+FoxP3+ Regulatory T Cells and Serum Cytokines in Sublingual and Subcutaneous Immunotherapy in Allergic Rhinitis with or without Asthma.
Int Arch Allergy Immunol 2019.
Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review.
CNS Drugs 2019.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×